Method for the production of thymocyte supernatant

Patent metadata

Field	Value
Publication number	US-11891624-B2
Application number	US-201916591351-A
Country	US
Kind code	B2
Filing date	Oct 2, 2019
Priority date	May 19, 2017
Publication date	Feb 6, 2024
Grant date	Feb 6, 2024

Abstract

Herein is reported a method for producing a thymocyte supernatant comprising the steps of co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2 in the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, and separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.

First claim

What is claimed is:

1. A method for producing a thymocyte supernatant comprising the following steps:
co-cultivating thymocytes and macrophages at a cell ratio of 0.5:1.2 to 0.5:2 in the presence of phorbol-12-myristate-13-acetate and phytohemagglutinin M for up to 60 hours, and
separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.

2. The method according to claim 1 , wherein the ratio is about 0.5:2.

3. The method according to claim 1 , wherein the thymocyte cell density is about 5×10 5 cells/ml in the co-cultivating.

4. The method according to claim 1 wherein prior to the co-cultivating the thymocytes are incubated for up to 60 hours at 37° C. in cultivation medium.

5. The method according to claim 1 , wherein the macrophages are isolated from PBMCs by adherence to a solid surface at a cell density of 2×10 6 cells/ml and the attached macrophages are incubated for about 40 hours in cultivation medium prior to the co-cultivating with the thymocytes.

6. The method according to claim 1 , wherein prior to the co-cultivating of the thymocytes and macrophages the cultivation medium of the thymocytes is replaced by fresh medium containing 10 ng/ml phorbol-12-myristate-13-acetate (PMA) and 5 μg/ml phytohemagglutinin M (PHA-M).

7. The method according to claim 1 , wherein the co-cultivating is started by removing the cultivation medium from the macrophages and adding the thymocyte suspension.

8. The method according to claim 1 , wherein the medium is RPMI medium supplemented with 10% (v/v) FCS, 1% (w/v) of a 200 mM glutamine solution that comprises penicillin and streptomycin, 2% (v/v) of a 100 mM sodium pyruvate solution, and 1% (v/v) of a 1 M 2-(4-(2-hydroxyethyl)-1-piperazine)-ethane sulfonic acid (HEPES) buffer, further comprising 0.05 μM β-mercaptoethanol.

Assignees

• Hoffmann La Roche

Inventors

• Offner Sonja
• Horvath Markus
• Saam Ingried

Classifications

• C12N5/0635 Primary

  B lymphocytes · CPC title

• C12N2500/30

  Organic components · CPC title

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• C12N2501/999

  Small molecules not provided for elsewhere · CPC title

• C12N2502/1114

  T cells · CPC title